BioMidwest

Found 78,251 articles

• Pregnancy Outcomes with COVID-19 Vaccines Reviewed in Journal of American Physicians and Surgeons (AAPS)

  3/21/2023

  The COVID-19 vaccine was developed and distributed with unprecedented speed, including to pregnant women.

• Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results

  3/21/2023

  Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the three-month and twelve-month periods ended December 31, 2022.

• Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update

  3/21/2023

  Predictive Oncology Inc. (Nasdaq: POAI), Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today reported financial and operating results for the year ended December 31, 2022, and provided a corporate update.

• Totality of Evidence from BeAT-HF Study Shows CVRx’s Barostim Provides Long-term Benefits for Patients with Heart Failure

  3/21/2023

  CVRx, Inc. (NASDAQ: CVRX) (“CVRx”) announced detailed preliminary results of the post-market phase of the BeAT-HF trial at the second annual Technology and Heart Failure (HF) Therapeutics (THT) conference on Tuesday, March 21, 2023.

• Broward Health Medical Center the First Hospital in Florida Using Advanced Genesis Robotic Technology to Treat Heart Rhythm Disorders

  3/20/2023

  Stereotaxis announced the grand opening of a new robotic electrophysiology program at Broward Health Medical Center in Fort Lauderdale, Florida.

• Societal CDMO Announces U.S. FDA Approval for Manufacturing of Commercial Tablet at Gainesville, Georgia Site

  3/20/2023

  Societal CDMO, Inc. announced that the United States Food and Drug Administration has approved the company as a manufacturer of a commercial tablet product.

• Surgalign Launches Next Generation Software for its HOLO Portal™ Surgical Guidance System and Expands Surgical Tool Integration to Drive Use Case Adoption

  3/20/2023

  Surgalign Holdings, Inc. today announced the first major upgrade of the HOLO Portal™ Surgical Guidance System since the first case was performed in May of 2022.

• Pharmazz Inc. Announces Key Publications Regarding the Role of Adrenergic Receptors in Venous Blood Return to Treat Shock

  3/20/2023

  Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced two key publications.

• INVO Signs Binding Agreements to Acquire Wisconsin Fertility Institute

  3/20/2023

  INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has signed binding agreements to acquire Wisconsin Fertility Institute.

• Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers by Their Partner Athenex Pharmaceutical Division (APD)

  3/20/2023

  Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced that its partner, Athenex Pharmaceutical Division, has just started to commercialize its abbreviated new drug application approval from the U.S. Food and Drug Administration for its Generic Version of Magnesium Sulfate in Water for Injection, 2 g/50 mL, 4 g/100 mL and 4 g/50 mL, in Non-PVC, Single-Patient Use Containers.

• CancerVAX CEO Ryan Davies Sits Down with Oncology Research Leader

  3/20/2023

  CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, reported that CEO Ryan Davies spoke with oncology researcher and biotech trailblazer Dr. David Bearss on his experience with cancer therapeutics and advice for young biotechnology companies.

• Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023

  3/20/2023

  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2022 financial results on Monday, March 27, 2023.

• DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023

  3/20/2023

  DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its full-year 2022 financial results will be released after the markets close on Tuesday, March 28th.

• Cleveland Clinic and IBM Unveil First Quantum Computer Dedicated to Healthcare Research

  3/20/2023

  Today, Cleveland Clinic and IBM (NYSE: IBM) officially unveiled the first deployment of an onsite private sector IBM-managed quantum computer in the United States.

• California Selects Civica Rx as Its Insulin Manufacturing Partner

  3/18/2023

  Civica Inc. announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.

• Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

  3/18/2023

  UCB, a global biopharmaceutical company, announced detailed positive results from two Phase 3 studies evaluating the efficacy and safety of bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa.

• AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy

  3/18/2023

  AbbVie announced new 52-week data from an open-label, single-arm study demonstrating improved plaque psoriasis signs and symptoms among a difficult-to-treat patient population who received SKYRIZI®, an IL-23 inhibitor.

• Pivotal Clinical SAHARA Study Shows Candesant Biomedical's Investigational Sweat Control Patch Significantly Reduces Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

  3/18/2023

  Candesant Biomedical announced findings from its pivotal clinical study of its investigational sweat control patch, the first three-minute patch for the significant reduction of excessive underarm sweating in patients with primary axillary hyperhidrosis.

• American Academy of Dermatology installs new officers, board members

  3/17/2023

  Three new officers and four new board members will be installed immediately upon conclusion of the 2023 Annual Meeting of the American Academy of Dermatology, the world's largest dermatologic society.

• CancerVax Universal Cancer Vaccine Being Developed by UCLA

  3/17/2023

  CancerVAX, Inc. announced that its sponsored research program with the University of California Los Angeles to research and develop a universal cancer vaccine is now fully under way.